|Bid||52.50 x 1300|
|Ask||52.51 x 800|
|Day's range||49.00 - 52.75|
|52-week range||49.00 - 96.48|
|Beta (5Y monthly)||0.71|
|PE ratio (TTM)||N/A|
|Earnings date||23 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||116.00|
STAMFORD, Conn., Jan. 04, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 8:15 am ET. A video webcast will be available on the Events & Presentations page within the Investors & M
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
SpringWorks Therapeutics (SWTX) collaborates with AbbVie (ABBV) to evaluate the combination of nirogacestat with AbbVie's ABBV-383 for relapsed or refractory multiple myeloma.